REPL — Replimune Group, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1737953 ·
Last close
$19.69
Market Cap
$1.87B
52W High
$23.54
52W Low
$1.50
ADV30
2,869,343
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -56,043,000 -57,121,000 373,940,000 307,833,000 169,162,000
Jun 2026 0 — -67,951,000 -69,766,000 252,447,000 185,359,000 146,802,000
Mar 2026 0 — -72,872,000 -73,217,000 332,388,000 209,024,000 166,228,000
Dec 2025 0 — -71,527,000 -70,930,000 333,590,000 122,951,000 123,051,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-245,546,000
Investing CF
$221,382,000
Financing CF
$227,477,000
CapEx
$-223,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.93
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,389,406,000
Inventory
$9,867,000
Receivables
$0
ST Investments
$0
EBIT TTM
$-260,616,000
Pretax Income TTM
$-271,585,000
Interest Exp TTM
$10,969,000
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 0 -318,315,000 -313,940,000 332,388,000 166,228,000 166,160,000 -280,344,000
Mar 2025 0 -259,854,000 -247,297,000 551,328,000 135,485,000 415,843,000 -192,250,000
Mar 2024 0 -232,853,000 -215,794,000 487,722,000 113,214,000 374,508,000 -185,467,000
Mar 2023 0 -174,166,000 -174,284,000 646,591,000 91,299,000 555,292,000 -128,050,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-297,013,000
OpCashFlow TTM
—
Assets (Latest)
$252,447,000
Forward EPS
$-0.67

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $19.00 · spot: $19.81 · call volume: 82 · put volume: 1,035
Expected Move to 2027-01-15: ±$5.10 (25.74%) — implied range $14.71 – $24.91 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
COAG Hemab Therapeutics Holdings, Inc. $1.83B $39.06 —
BCRX BIOCRYST PHARMACEUTICALS INC $1.93B $7.50 —
MAZE Maze Therapeutics, Inc. $1.80B $32.87 —
RXRX RECURSION PHARMACEUTICALS, INC. $1.69B $2.72 —
BEAM Beam Therapeutics Inc. $2.14B $20.65 —

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet
2026-11-18 13:55 · Yahoo
How Investors May Respond To Replimune Group (REPL) Narrower Quarterly Loss
2026-11-05 08:19 · Yahoo
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
2026-11-02 13:55 · Yahoo
Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians
2026-10-29 18:41 · Yahoo
Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
2026-10-29 03:07 · Yahoo
Is Replimune Group (REPL) Cheap Following Its Reduced Net Loss Results?
2026-10-29 02:07 · Yahoo
Replimune: 3 Key Takeaways for Long-Term Investors
2026-10-29 01:33 · Yahoo
Replimune (REPL) Q2 2027 Earnings Call Transcript
2026-10-28 22:44 · Yahoo
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
2026-10-28 11:00 · Yahoo
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
2026-10-22 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.